Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Acceptable safety profile described for NBI-3001 in recurrent malignant glioma

Sep. 19, 2003

Aastrom receives SBIR grant for dendritic cell vaccine research

Sep. 18, 2003

Enrollment completed in phase I breast cancer trial for HER-2 AutoVac Protein vaccine

Sep. 15, 2003

Phase I/II trial approved to evaluate Collidem in colorectal cancer

Sep. 12, 2003

Antisoma acquires Cytogen's R-1549 royalty rights

Sep. 12, 2003

Private equity financing to advance development of Panvac-VF and Prostvac-VF

Sep. 12, 2003

New phase II trial evaluates MDX-010 for metastatic breast cancer

Sep. 10, 2003

Provenge receives fast track designation

Sep. 8, 2003

Partial clinical hold on phase III Oncophage trials

Sep. 5, 2003

New phase I/II trial to evaluate Xcellerated T Cells in treatment of CLL

Sep. 2, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...